

A06 – RESISTANCE MECHANISMS OF GLIOBLASTOMA AGAINST ALKYLATING AGENTS AND RADIOTHERAPY

Violaine Goidts & Felix Sahm



SUMMARY

In this project, loss-of-function screens will be performed to decipher the mechanisms of *isocitrate dehydrogenase (IDH)* wildtype glioblastoma resistance to alkylating agents and radiotherapy. Presence and activation of these mechanisms will also be confirmed on human glioma tissue, also with regard to intra-tumoral heterogeneity. We aim to overcome current therapy resistance and ultimately recurrence of glioblastoma.


TASK

VISUAL ABSTRACT

WORKFLOW

Task 1 –


Identification of drug targets to increase chemo- and radiotherapy sensitivity



- (Epi-)genomic and translational characterization of recurrent and newly diagnosed glioblastoma samples with MGMT methylated or unmethylated promoter.
- Loss-of-function screen with or without temozolomide or high-dose irradiation.
- Selection of the best hits.

Task 2 –


In vitro validation of the identified hits



- Validation via CRISPR/Cas9 system (FACS, caspase assay,...).
- Confirmation of the phenotype using available inhibitors and selection of the most effective and selective one.
- (Epi-)genomic and transcriptional monitoring of the inhibition.

Task 3 –


In vivo preclinical studies of small-molecule inhibitors to target recurrent glioblastoma and increase current therapies sensitivity



- Establishment of orthotopic PDX models (including monitoring of the genetic changes by high-throughput sequencing).
- In vivo test of the established combinatorial treatments from tasks 1 and 2.

Task 4 –

Assessment of potential clonal selection of the combinatory treatment



- Verification of a potential clonal selectivity of the treatment by single-cell sequencing using
- IDH mutant mouse model
 - Confetti mouse model
 - Optical barcoding